Skip to content

Molecure vs Syntara

Molecure logo

Molecure

Fate can be altered

85 employees · est. 2012 · Warsaw, Poland

VS
Syntara logo

Syntara

Syntara (ASX:SNT) is an ASX-listed clinical stage drug developer for diseases linked to fibrosis and inflammation

58 employees · est. 1998 · Australia

Syntara is the older company (2012 vs 1998).

Side-by-Side Comparison

Molecure Syntara
Founded
2012 1998 older
Headquarters
Warsaw, Poland Australia
Employees
85 58
Industry
Biopharma, Biotechnology, Health and Wellness Biotechnology, Health Care, Pharmaceutical
Funding Stage
Post-IPO Secondary Post-IPO Equity
Total Funding
$50.00M $1.39M
Funding Rounds
1 1
Taxonomy
BiopharmaceuticalClinical StageSmall Molecule Drug DiscoveryImmunotherapyMedicinal ChemistryRespiratory Diseases +9 Clinical Stage Drug DevelopmentExtracellular Matrix DysfunctionAmine Oxidase ChemistryDrug CandidatesFibrotic DiseasesInflammatory Diseases +9
Website
molecure.com syntaratx.com.au
Molecure logo

About Molecure

Molecure is a clinical stage biopharmaceutical company based in Poland. Since its establishment in 2012, the company has been dedicated to utilizing its world-leading medicinal chemistry capabilities to address unmet medical needs. Molecure's approach involves discovering and developing first-in-cla...

Syntara logo

About Syntara

Syntara (ASX:SNT) is a clinical stage drug developer focusing on diseases associated with fibrosis and inflammation. The company, founded in 1998, specializes in targeting extracellular matrix dysfunction using its expertise in amine oxidase chemistry. Its lead candidate SNT-5505 has received FDA Or...

Also comparing in this category

Comparing more than these two?

Get Molecure, Syntara and up to nine more competitors side by side in one PDF: team, funding, traffic and every dated move of the last six months. Every company is re-checked on the day you order.

How does Molecure compare?

A PDF of Molecure and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Rival Readout

Comparing competitors? We do this properly.

10 rivals, 90 days of dated moves in 7 business days: a ranked list of what matters, each with its source, ending in a 60-minute readout with your team.

Frequently Asked Questions

Molecure was founded in 2012, based in Warsaw, Poland, with 85 employees. Molecure is a clinical stage biopharmaceutical company based in Poland. Since its establishment in 2012, the company has been dedicated to utilizing its world-leading medicinal chemistry capabilities. Syntara was founded in 1998, based in Australia, with 58 employees. Syntara (ASX:SNT) is a clinical stage drug developer focusing on diseases associated with fibrosis and inflammation. The company, founded in 1998, specializes in targeting extracellular matrix dysfunc.
Molecure has raised $50.00M and Syntara $1.39M. Latest stage: Molecure Post-IPO Secondary, Syntara Post-IPO Equity.
Both work in Biotechnology and list inflammatory diseases and fibrotic diseases among their focus areas.

Compare Molecure with someone else

Start typing a company name or domain.

Compiled from the BounceWatch company index. We last looked at Molecure on 12 Sep 2024, and Syntara on 6 Dec 2024. Where a field is blank here, it means we have not recorded it — not that the answer is zero. How we source and date this.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout